This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Abstract Aim: The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. Methods: (a) We retrospectively investigated seven patients who underwent emergency surgery for bevacizumab-associated intestinal perforation. (b) We investigated 104 patients with advanced colorectal cancer treated with neoadjuvant therapy who underwent surgery from 2008 to 2018, retrospectively. Results: (a) In the seven patients undergoing emergency surgery for gastrointestinal perforation, the median bevacizumab administration and washout periods were 16 weeks and 24 days, respectively. A stoma was created in all patients except in those who were not candidates. Two patients developed postoperative abdominal abscesses, and two patients died from perioperative sepsis and gastrointestinal bleeding, respectively; both of these patients had poor performance status. (b) In patients receiving bevacizumab (n = 45) and patients treated with bevacizumab-free regimens as neoadjuvant therapy (n = 59), 31 and 52 patients received chemoradiotherapy, respectively. We found no correlation with postoperative complications with or without bevacizumab. Conclusion: The surgical indications should be considered carefully in patients with gastrointestinal perforation secondary to bevacizumab administration. Meanwhile, after appropriate cessation time, scheduled surgery following bevacizumab administration is feasible. K E Y W O R D S bevacizumab, cancer, emergencies, perforation, postoperative complications How to cite this article: Yoshimoto T, Yoshikawa K, Higashijima J, et al. Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab. Ann Gastroenterol Surg. 2020;4:151-155. https ://doi.
| INTRODUC TI ON
Bevacizumab is a molecular-targeted drug used for colorectal cancer, non-small cell lung cancer, breast cancer, and malignant glioma. [1] [2] [3] Vascular endothelial growth factor (VEGF) plays an important role in tumor proliferation, invasion, and metastasis by promoting angiogenesis. 4 Furthermore, VEGF is known to be associated with recurrence and prognosis, 2 and its inhibition is an important factor for treatment. 5 Bevacizumab specifically binds to VEGF-A and inhibits its binding to VEGF receptor (VEGFR)-1 and VEGFR-2, thereby inhibiting VEGF signal transduction. 3 In colorectal cancer, many patients present with advanced disease or develop metastases within the first years after curative surgery, 6 and bevacizumab has contributed to meaningful improvements in survival in patients with advanced colorectal cancer in recent years. [7] [8] [9] In Japan, some regimens including bevacizumab are recommended as first-line therapy for unresectable colorectal cancer. 10 Furthermore, bevacizumab is used in both palliative and neoadjuvant settings. 1 However, bevacizumab has also been associated with significant side effects. [11] [12] [13] In patients who have not undergone surgery, bevacizumab has been associated with hypertension (3.0%-15.0%), proteinuria (0.7%-1.0%), diarrhea (4.0%-39.9%), arterial (0.9%-10.0%) and venous (2.7%-14.9%) thromboembolism, hemorrhage (1.4%-5.0%), and gastrointestinal perforation (0.6%-2.9%). 3, [14] [15] [16] Postoperatively, gastrointestinal perforation (2.0%-20.0%), wound infection (1.5%-11.1%), wound healing issues (2.0%-9.7%), hemorrhage (2.7%), and anastomotic dehiscence (2.0%) are attributed to the use of bevacizumab. 15 The inhibition of VEGF signal transduction, which affects angiogenesis, may impact healing and cause gastrointestinal peroration. 17 Bowel perforation is a serious complication, and immediate recognition followed by surgical intervention is the best management for this potentially fatal complication. 1, 5, 13 The fatality rate in patients with gastrointestinal perforation treated with bevacizumab was reported to be as high as 20%. 2, 18 In this report, we investigated patients undergoing emergency surgery who developed gastrointestinal perforation during bevacizumab administration, and patients with advanced colorectal cancer who could safely undergo surgery after a washout period for bevacizumab.
| ME THODS
This study was performed in accordance with the Helsinki Thirty patients in the bevacizumab group received radiotherapy with S-1/Oxaliplatin/Bevacizumab (SOX + Bev) in a clinical study (UMIN000006937). The radiation dose at CRT was 40 Gy for all SOX + Bev, S-1, and UFT regimens.
| Statistical analysis
We used the Chi-square test, and P-values < .05 were considered statistically significant. All statistical analyses were performed using JMP version 13 statistical software (SAS Institute Inc). Table 1 shows the details of the seven patients who developed Table 2 shows a comparison of bevacizumab-administrated patients and patients treated with bevacizumab-free regimens as neoadjuvant therapy with or without radiotherapy. In the without-radiotherapy group (n = 21), 14 patients received bevacizumab. In contrast, 31 patients were treated with bevacizumab in the chemoradiotherapy group. We found no correlation between bevacizumab administration and the occurrence of postoperative complications of Clavien-Dindo classification grade III or higher. Additionally, patients in the bevacizumab-free group developed complications such as suture leakage and stoma necrosis.
| RE SULTS

| Study 1. Bevacizumab-induced intestinal perforation
| Study 2. Comparison of patients receiving and not receiving bevacizumab
| D ISCUSS I ON
This report revealed that planned surgery is feasible following bevacizumab administration with appropriate cessation time. In addition, in patients developing gastrointestinal perforation during bevacizumab administration, it is desirable to construct a stoma without anastomosis, and it is necessary to consider the patient's current disease status and performance status regarding the surgical indications. Bevacizumab, a monoclonal antibody to soluble VEGF, has an important and evolving role in improving outcomes for patients with unresectable colorectal cancer. 7, 15 Molecularlytargeted agents are generally safe and less toxic than cytotoxic agents 4, 19, 20 ; however, previous reports showed that bevacizumab administration is a risk factor for gastrointestinal perforation, which is partly related to primary tumor perforation. 8, 12 The risk factors for gastrointestinal perforation include high-dose administration of bevacizumab, acute diverticulitis, bowel obstruction, recent history of sigmoidoscopy or colonoscopy, history of pelvic or abdominal irradiation, carcinomatous peritonitis, peptic ulcer, and administration of steroids or nonsteroidal anti-inflammatory drugs. 19, 21 Bevacizumab exerts antitumor effects by causing ischemic changes, such as microvascular involution in tumors and suppression of neovascularization in the tumor tissue. In the first, the inhibition of VEGF by bevacizumab could cause a decrease in vascular density, disorders of vasoconstriction secondary to the arterial thrombus, and embolism as a result of failure of blood vessel structure and functional disorders. 2, 19 The second possible mechanism is related to the gastrointestinal mucosa. Constant gastrointestinal wall proliferation and healing are dependent on microcirculation, protection with nitrous oxide, and normal platelet function, all of which depend on VEGF. 2 Intestinal healing after damage such as that following surgery, or ulcers, is also dependent on these processes. According to these mechanisms, nonsteroidal anti-inflammatory drugs are a risk factor for bevacizumab-related gastrointestinal perforation. In a previous animal experimental study, preoperative administration of bevacizumab inhibited angiogenesis and also decreased α-smooth muscle actin accumulation and collagen deposition in the intestinal anastomotic tissue. 1 The third possible mechanism is, ironically, the great efficacy of bevacizumab to reduce tumor volume. Tumor structure may provide some stability to the intestinal wall itself, and tumor death caused by bevacizumab creates perforation. 2 Of gastrointestinal perforations induced by bevacizumab, 80% occur within 6 months after initial bevacizumab administration. 21 The most common site of perforation is the colon, followed by the small intestine and stomach. 13, 21 In this study, intestinal perforations occurred within 6 months after initial bevacizumab administration in all patients, and primary tumor perforation occurred in two patients. As a risk factor, one patient had cancerous peritonitis.
The timing of therapy relative to surgery has been shown to be critically important because of the long half-life of bevacizumab. 15 Because the half-life of bevacizumab is about 20 days, 11, 19, 22 for a drug-free interval of a minimum of 6 weeks and some as high as 60 days to help prevent wound-healing complications. 12, 15, 20, 22 In this study, all patients except one underwent a 4-week cessation period with planned surgery, and none developed severe ous meta-analyses of bevacizumab randomized controlled trials showed no significant difference in perforation rates between different concomitant medications or regimens. 23, 24 Also, in this study, there was no correlation between the number of regimens and postoperative complications with or without radiation therapy (data not shown).
The incidence of gastrointestinal perforation after radiotherapy has been reported to be around 2% for doses below 50 Gy and 14% above 50 Gy 25 ; however, in this study, all patients underwent 40 Gy irradiation. Furthermore, the interval from irradiation to surgery was 6-8 weeks in all cases, but according to past meta-analysis, the complication rate was the same even if the interval was longer than 6-8 weeks. 26 In patients undergoing emergency surgery, we constructed a stoma unless the patient was not a candidate. The main limitations of this study are the limited number of patients and patients' different backgrounds. Because bevacizumab is used in a growing number of people with metastatic colorectal cancer, surgeons will have to operate increasingly frequently in this high-risk population. 11 In conclusion, we recommend that the surgical indications be considered carefully in patients with severe gastrointestinal perforation secondary to bevacizumab administration. However, after an appropriate cessation time, scheduled surgery is feasible following bevacizumab administration.
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